RXi Reports Positive Phase 2 Clinical Trial Results

On May 18, RXi Pharmaceuticals Corporation (RXII) reported positive results from its phase 2 clinical trial of the drug Samcyprone for the treatment of common warts. After weekly application for 10 weeks, participants had a 97.7% positive immunotherapy response rate. 70% of participants experienced a reduction of at least 50% wart size. There is currently no prescription drug approved by the FDA for the treatment of common warts.

Sonal caught the news and sent an alert at 11:58 am. The next trade took place at 11:59 am for $2.45. The stock closed at $2.58 for a gain of over 5% on the event day.

If you want to learn more about trading on clinical trial results, visit the Knowledge Center.

To see the latest weekly webinar, you can visit our Live Webinar page.

Subscribe here if you would like to start receiving these signals in real-time and start trading!